MX2011009271A - Nuevo compuesto de alfa-(n-sulfonamido)acetamida como inhibidor de la produccion del peptido beta amiloide. - Google Patents

Nuevo compuesto de alfa-(n-sulfonamido)acetamida como inhibidor de la produccion del peptido beta amiloide.

Info

Publication number
MX2011009271A
MX2011009271A MX2011009271A MX2011009271A MX2011009271A MX 2011009271 A MX2011009271 A MX 2011009271A MX 2011009271 A MX2011009271 A MX 2011009271A MX 2011009271 A MX2011009271 A MX 2011009271A MX 2011009271 A MX2011009271 A MX 2011009271A
Authority
MX
Mexico
Prior art keywords
sulfonamido
inhibitor
amyloid peptide
beta amyloid
peptide production
Prior art date
Application number
MX2011009271A
Other languages
English (en)
Inventor
John E Starrett Jr
Richard E Olson
Kevin W Gillman
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2011009271A publication Critical patent/MX2011009271A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención proporciona un método para el tratamiento del trauma de la cabeza, lesión traumática del cerebro, y/o demencia pugilística, que comprende administrar una cantidad terapéuticamente efectiva de (2R)-2-[[(4-clorofenil)sulfonil] [[2-fluoro-4-(1,2,4-oxadiazol-3-il)fenil]metil]amino]-5,5,5-trifl uoropentanamida.
MX2011009271A 2009-03-19 2009-03-19 Nuevo compuesto de alfa-(n-sulfonamido)acetamida como inhibidor de la produccion del peptido beta amiloide. MX2011009271A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2009/037639 WO2010107435A1 (en) 2009-03-19 2009-03-19 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Publications (1)

Publication Number Publication Date
MX2011009271A true MX2011009271A (es) 2011-09-26

Family

ID=40940246

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009271A MX2011009271A (es) 2009-03-19 2009-03-19 Nuevo compuesto de alfa-(n-sulfonamido)acetamida como inhibidor de la produccion del peptido beta amiloide.

Country Status (15)

Country Link
EP (1) EP2408450B1 (es)
JP (1) JP2012520875A (es)
KR (1) KR20110133046A (es)
CN (1) CN102438622A (es)
AU (1) AU2009342632A1 (es)
BR (1) BRPI0924404A2 (es)
CA (1) CA2755738A1 (es)
EA (1) EA201171143A1 (es)
ES (1) ES2406363T3 (es)
IL (1) IL214629A0 (es)
MX (1) MX2011009271A (es)
NZ (1) NZ594561A (es)
SG (1) SG173797A1 (es)
WO (1) WO2010107435A1 (es)
ZA (1) ZA201106206B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0215182A (pt) 2001-12-20 2004-10-19 Bristol Myers Squibb Co Derivados de (alfa)- (n-sulfonamido) acetamida como inibidores de (beta)-amilóide
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
DE112015001826T5 (de) 2014-04-17 2016-12-22 Sumitomo Chemical Company, Limited Verfahren zur Herstellung einer Nitroverbindung

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9817348D0 (en) * 1998-08-11 1998-10-07 British Biotech Pharm Pharmaceutical use of esters
BR0215182A (pt) * 2001-12-20 2004-10-19 Bristol Myers Squibb Co Derivados de (alfa)- (n-sulfonamido) acetamida como inibidores de (beta)-amilóide
GB0313772D0 (en) * 2003-06-13 2003-07-23 Merck Sharp & Dohme Therapeutic treatment
ATE446285T1 (de) * 2003-12-03 2009-11-15 Merck & Co Inc Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren
JP2007538024A (ja) * 2004-05-19 2007-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物
AU2008215948A1 (en) * 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
US8501813B2 (en) * 2007-08-09 2013-08-06 Kabushiki Kaisha Yakult Honsha γ-secretase inhibitor
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Also Published As

Publication number Publication date
BRPI0924404A2 (pt) 2019-04-02
EP2408450B1 (en) 2013-03-13
JP2012520875A (ja) 2012-09-10
CN102438622A (zh) 2012-05-02
KR20110133046A (ko) 2011-12-09
AU2009342632A1 (en) 2011-09-01
NZ594561A (en) 2013-03-28
WO2010107435A8 (en) 2011-10-13
ZA201106206B (en) 2013-01-30
WO2010107435A1 (en) 2010-09-23
IL214629A0 (en) 2011-09-27
SG173797A1 (en) 2011-09-29
EP2408450A1 (en) 2012-01-25
ES2406363T3 (es) 2013-06-06
EA201171143A1 (ru) 2012-03-30
CA2755738A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
MX2010004319A (es) Compuesto de alfa-(n-sulfonamido)acetamida novedoso como un inhibidor de producccion de peptido beta amiloide.
CL2014000492A1 (es) Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras
MY152595A (en) 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide monohydrate
TW200619220A (en) New hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5, 6, 7, 8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-mithoxy-n-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
NZ596579A (en) Bace inhibitors
MX2013013692A (es) Halogenoalquil-1,3-oxazinas como inhibidores de beta secretasa 1 (bace1) y/o beta secretasa 2 (bace2).
ZA200707531B (en) N-(N-Sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
TNSN07048A1 (en) Trifluoromethyl substituted benzamides as kinase inhibitors
PT2222669E (pt) Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)
MX2009011276A (es) Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad.
IL201309A0 (en) Novel n - (8 - heteroaryltetrahydronaphtalene - 2yl) or n - (5 - heteroarylchromane - 3 - yl) carboxamide derivatives for the treatment of pain
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
MX2014003408A (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
MX2011009271A (es) Nuevo compuesto de alfa-(n-sulfonamido)acetamida como inhibidor de la produccion del peptido beta amiloide.
NZ596000A (en) Carboxamide compounds and their use as calpain inhibitors
TW200612922A (en) Inhibitors of hsp90
MX2013014194A (es) 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
NZ595335A (en) Pharmaceutical comprising (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide with enhanced bioavailability and solubility
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
AR075903A1 (es) Compuestos de alfa-(sulfonamido)acetamida que incorporan deuterio como inhibidores de la produccion de peptido beta amiloide.
IL184355A0 (en) Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
MY148880A (en) N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
DE602006019830D1 (de) Tetrahydro- und dihydrochinazolinone
IL184236A0 (en) Glycine reuptake inhibitors for treatment of drug dependence

Legal Events

Date Code Title Description
FA Abandonment or withdrawal